Table 3 Proteins significantly associated with incident metabolic syndrome (MetS, number of events = 109) in the PIVUS study during 5 years follow-up. OR, odds ratio

Hepatocyte growth factor (HGF)

1.93 (1.46, 2.55)

3.23*10^–6

Interleukin-1 receptor antagonist protein (IL-1RA)

1.76 (1.38, 2.24)

4.32*10^–6

Leptin (LEP)

1.88 (1.42, 2.48)

.000011

Fatty acid-binding protein 4 (FABP4)

1.76 (1.33, 2.32)

.000065

Tumor necrosis factor ligand superfamily member 14 (TNFSF14)

1.52 (1.20, 1.92)

.00049

Vascular endothelial growth factor A (VEGF-A)

1.54 (1.2, 1.96)

.00055

Growth/differentiation factor 15 (GDF-15)

1.67 (1.24, 2.24)

.00061

Myoglobin (MB)

1.48 (1.16, 1.90)

.0017

Cathepsin D (CTSD)

1.49 (1.14, 1.94)

.0036

Stem cell factor (SCF)

0.71 (0.57, 0.90)

.0041

Matrix metalloproteinase-12 (MMP-12)

1.47 (1.12, 1.93)

.0060

Galanin peptides (GAL)

0.73 (0.56, 0.94)

.015

Cystatin-B (CSTB)

1.34 (1.06, 1.71)

.016

Placenta growth factor (PlGF)

1.34 (1.05, 1.71)

.019

Fractalkine (CX3CL1)

0.76 (0.60, 0.96)

.021

Interleukin-6 (IL-6)

1.27 (1.03, 1.57)

.022

Matrix metalloproteinase-7 (MMP-7)

1.22 (1.03, 1.45)

.022

Vascular endothelial growth factor D (VEGF-D)

0.75 (0.58, 0.97)

.029

Tissue factor (TF)

0.76 (0.59, 0.97)

.030

TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)

1.31 (1.03, 1.67)

.030

Tissue-type plasminogen activator (t-PA)

1.32 (1.02, 1.7)

.034

E-selectin (SELE)

1.3 (1.01, 1.67)

.039